Telix Pharmaceuticals is trading 5.58% down now at A$16.76 as investors take profits following Pixclara’s FDA approval.

  • The approval remains a major positive catalyst.
  • The stock gained 8.63% to A$17.75 on September 15.
  • Broader biotech weakness, with XBI down 2.11%, likely added pressure as sector sentiment deteriorated.